Bibliographies thématiques / Nanomagnetism - Small Molecular Organic Ligands

Sommaire

  1. Articles de revues
  2. Thèses

Littérature scientifique sur le sujet « Nanomagnetism - Small Molecular Organic Ligands »

Auteur : Grafiati
Publié le 7 septembre 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Nanomagnetism - Small Molecular Organic Ligands ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Nanomagnetism - Small Molecular Organic Ligands"

1

Milanesi, Eva, Paola Costantini, Alberto Gambalunga, et al. "The Mitochondrial Effects of Small Organic Ligands of BCL-2." Journal of Biological Chemistry 281, no. 15 (2006): 10066–72. http://dx.doi.org/10.1074/jbc.m513708200.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Nilsson, K. Peter R. "Small organic probes as amyloid specific ligands - Past and recent molecular scaffolds." FEBS Letters 583, no. 16 (2009): 2593–99. http://dx.doi.org/10.1016/j.febslet.2009.04.016.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Reiner, Thomas, Sarah Earley, Anna Turetsky, and Ralph Weissleder. "Bioorthogonal Small-Molecule Ligands for PARP1 Imaging in Living Cells." ChemBioChem 11, no. 17 (2010): 2374–77. http://dx.doi.org/10.1002/cbic.201000477.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Wijtmans, Maikel, Dennis Verzijl, Rob Leurs, Iwan J. P. de Esch, and Martine J Smit. "Towards Small-Molecule CXCR3 Ligands with Clinical Potential." ChemMedChem 3, no. 6 (2008): 861–72. http://dx.doi.org/10.1002/cmdc.200700365.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Blalock, J. E. "On the evolution of ligands: did peptides functionally precede metals and small organic molecules?" Cellular and Molecular Life Sciences (CMLS) 55, no. 4 (1999): 513–18. http://dx.doi.org/10.1007/s000180050309.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Scodeller, Pablo, and Eliana K. Asciutto. "Targeting Tumors Using Peptides." Molecules 25, no. 4 (2020): 808. http://dx.doi.org/10.3390/molecules25040808.

Texte intégral
Résumé :
To penetrate solid tumors, low molecular weight (Mw < 10 KDa) compounds have an edge over antibodies: their higher penetration because of their small size. Because of the dense stroma and high interstitial fluid pressure of solid tumors, the penetration of higher Mw compounds is unfavored and being small thus becomes an advantage. This review covers a wide range of peptidic ligands—linear, cyclic, macrocyclic and cyclotidic peptides—to target tumors: We describe the main tools to identify peptides experimentally, such as phage display, and the possible chemical modifications to enhance the properties of the identified peptides. We also review in silico identification of peptides and the most salient non-peptidic ligands in clinical stages. We later focus the attention on the current validated ligands available to target different tumor compartments: blood vessels, extracelullar matrix, and tumor associated macrophages. The clinical advances and failures of these ligands and their therapeutic conjugates will be discussed. We aim to present the reader with the state-of-the-art in targeting tumors, by using low Mw molecules, and the tools to identify new ligands.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Kim, Hyeon Jin, Mi Suk Jeong, and Se Bok Jang. "Molecular Characteristics of RAGE and Advances in Small-Molecule Inhibitors." International Journal of Molecular Sciences 22, no. 13 (2021): 6904. http://dx.doi.org/10.3390/ijms22136904.

Texte intégral
Résumé :
Receptor for advanced glycation end-products (RAGE) is a member of the immunoglobulin superfamily. RAGE binds and mediates cellular responses to a range of DAMPs (damage-associated molecular pattern molecules), such as AGEs, HMGB1, and S100/calgranulins, and as an innate immune sensor, can recognize microbial PAMPs (pathogen-associated molecular pattern molecules), including bacterial LPS, bacterial DNA, and viral and parasitic proteins. RAGE and its ligands stimulate the activations of diverse pathways, such as p38MAPK, ERK1/2, Cdc42/Rac, and JNK, and trigger cascades of diverse signaling events that are involved in a wide spectrum of diseases, including diabetes mellitus, inflammatory, vascular and neurodegenerative diseases, atherothrombosis, and cancer. Thus, the targeted inhibition of RAGE or its ligands is considered an important strategy for the treatment of cancer and chronic inflammatory diseases.
Styles APA, Harvard, Vancouver, ISO, etc.
8

Tassinari, Martina, Alberto Lena, Elena Butovskaya, et al. "A Fragment-Based Approach for the Development of G-Quadruplex Ligands: Role of the Amidoxime Moiety." Molecules 23, no. 8 (2018): 1874. http://dx.doi.org/10.3390/molecules23081874.

Texte intégral
Résumé :
G-quadruplex (G4) nucleic acid structures have been reported to be involved in several human pathologies, including cancer, neurodegenerative disorders and infectious diseases; however, G4 targeting compounds still need implementation in terms of drug-like properties and selectivity in order to reach the clinical use. So far, G4 ligands have been mainly identified through high-throughput screening methods or design of molecules with pre-set features. Here, we describe the development of new heterocyclic ligands through a fragment-based drug discovery (FBDD) approach. The ligands were designed against the major G4 present in the long terminal repeat (LTR) promoter region of the human immunodeficiency virus-1 (HIV-1), the stabilization of which has been shown to suppress viral gene expression and replication. Our method is based on the generation of molecular fragment small libraries, screened against the target to further elaborate them into lead compounds. We screened 150 small molecules, composed by structurally and chemically different fragments, selected from commercially available and in-house compounds; synthetic elaboration yielded several G4 ligands and two final G4 binders, both embedding an amidoxime moiety; one of these two compounds showed preferential binding for the HIV-1 LTR G4. This work presents the discovery of a novel potential pharmacophore and highlights the possibility to apply a fragment-based approach to develop G4 ligands with unexpected chemical features.
Styles APA, Harvard, Vancouver, ISO, etc.
9

Gómez-Santacana, Xavier, Sabrina M. de Munnik, Tamara A. M. Mocking, et al. "A toolbox of molecular photoswitches to modulate the CXCR3 chemokine receptor with light." Beilstein Journal of Organic Chemistry 15 (October 23, 2019): 2509–23. http://dx.doi.org/10.3762/bjoc.15.244.

Texte intégral
Résumé :
We report a detailed structure–activity relationship for the scaffold of VUF16216, a compound we have previously communicated as a small-molecule efficacy photoswitch for the peptidergic chemokine GPCR CXCR3. A series of photoswitchable azobenzene ligands was prepared through various synthetic strategies and multistep syntheses. Photochemical and pharmacological properties were used to guide the design iterations. Investigations of positional and substituent effects reveal that halogen substituents on the ortho-position of the outer ring are preferred for conferring partial agonism on the cis form of the ligands. This effect could be expanded by an electron-donating group on the para-position of the central ring. A variety of efficacy differences between the trans and cis forms emerges from these compounds. Tool compounds VUF15888 (4d) and VUF16620 (6e) represent more subtle efficacy switches, while VUF16216 (6f) displays the largest efficacy switch, from antagonism to full agonism. The compound class disclosed here can aid in new photopharmacology studies of CXCR3 signaling.
Styles APA, Harvard, Vancouver, ISO, etc.
10

Porter, John, Andrew Payne, Ian Whitcombe, et al. "Atropisomeric small molecule Bcl-2 ligands: Determination of bioactive conformation." Bioorganic & Medicinal Chemistry Letters 19, no. 6 (2009): 1767–72. http://dx.doi.org/10.1016/j.bmcl.2009.01.071.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Thèses sur le sujet "Nanomagnetism - Small Molecular Organic Ligands"

1

Soules, Régis. "Proprietes cooperatives de complexes polymetalliques des ligands squarate et thiosquarate." Toulouse 3, 1987. http://www.theses.fr/1987TOU30178.

Texte intégral
Résumé :
Etude de l'emploi d'un coordinat assembleur qui puisse par coordination avec le centre metallique utilise (metaux de transition du groupe viii) aboutir a un agencement a une dimension des motifs moleculaires par empilement d'entites monomeres ou par formation de chaines. Par utilisation du coordinat squarate sous ses formes oxygenees et soufrees, obtention d'un certain nombre de complexes de pt, pd, ni et cu repondant aux criteres fixes. Etude des structures de ces composes, de leurs proprietes physiques et de la relation structure-propriete. La nature du coordinat comme le caractere specifique de l'arrangement structural ont ete discutes pour une approche de la comprehension de la nature de ces proprietes physiques
Styles APA, Harvard, Vancouver, ISO, etc.
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie